Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Northwest Biotherapeutics (NWBO) Enterprise Value (2016 - 2025)

Northwest Biotherapeutics' Enterprise Value history spans 16 years, with the latest figure at -$3.0 million for Q4 2025.

  • Quarterly results put Enterprise Value at -$3.0 million for Q4 2025, down 39.77% from a year ago — trailing twelve months through Dec 2025 was -$3.0 million (down 39.77% YoY), and the annual figure for FY2025 was -$3.0 million, down 39.77%.
  • Enterprise Value for Q4 2025 was -$3.0 million at Northwest Biotherapeutics, up from -$4.6 million in the prior quarter.
  • In the past five years, Enterprise Value ranged from a high of -$1.4 million in Q2 2023 to a low of -$15.2 million in Q4 2021.
  • The 5-year median for Enterprise Value is -$4.1 million (2021), against an average of -$5.0 million.
  • The sharpest move saw Enterprise Value tumbled 877.49% in 2021, then surged 70.52% in 2023.
  • Year by year, Enterprise Value stood at -$15.2 million in 2021, then surged by 54.08% to -$7.0 million in 2022, then soared by 69.48% to -$2.1 million in 2023, then decreased by 2.3% to -$2.2 million in 2024, then crashed by 39.77% to -$3.0 million in 2025.
  • According to Business Quant data, Enterprise Value over the past three periods came in at -$3.0 million, -$4.6 million, and -$4.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.